Cheryl Renee Blanchard
Executive ChairDr. Cheryl Renee Blanchard, Ph.D., serves as Executive Chair of Anika Therapeutics, Inc. since February 1, 2026. At Anika Therapeutics, Inc., she also served as President, CEO & Director from April 26, 2020 to February 1, 2026, as Interim CEO & Director from February 10, 2020 to April 26, 2020, and as Independent Director from August 2018 to February 10, 2020. She joined the firm in August 2018. She serves as Executive in Residence at Clarevia Ventures, which she joined on July 30, 2026. She also serves as an Independent Director of Xilio Therapeutics, Inc. since April 15, 2026, as a Director of Lumicell Inc. since February 2026, as a Director of Surgicure Technologies, Inc., and as a Director of Elute, Inc. since May 2013. She is also a Member of the Scientific Advisory Board of Novum Medical, Inc. since July 2019. Dr. Blanchard served as an Independent Director of Vigil Neuroscience, Inc. from November 2020 to August 2025 and as an Independent Director of Daré Bioscience, Inc. from November 2019 to June 2024. She was an Independent Director of Neuronetics, Inc. from February 13, 2019 to June 26, 2020. From September 2012 to April 2020, she was a Principal of Blanchard Consulting, LLC. She served as Chief Executive Officer, President, and Director at Microchips Biotech, Inc. from July 21, 2014 to November 2019 and as President and Chief Executive Officer of Dare MB Inc. from 2014 to November 2019. From July 2018 to July 2019, Dr. Blanchard served as President and Chief Executive Officer of Keratin Biosciences, Inc. She served as Director of Novum Medical, Inc. until July 2019 and as Director of SeaSpine Holdings Corporation from July 2015 to May 30, 2019. She served as Chief Scientific Officer and Senior Vice President of Zimmer Biomet Holdings, Inc. During her tenure from 2000 to 2012, she also served as General Manager of Zimmer Biologics, Senior Vice President of Research and Development, Vice President of Corporate Research and Clinical Affairs, and Vice President of Research and Biologics. She joined the company in October 2000 as Director of Research. She also served as a Director of Isto Biologics. Prior to this, she served in leadership roles at the Southwest Research Institute, the University of Texas Health Science Center, and the Oak Ridge National Laboratory. She also served as an adjunct professor at the University of Texas Health Science Center. Dr. Blanchard is a medical device and biologics executive. In 2015, she was elected to the National Academy of Engineering. During her several years with Zimmer, Dr. Blanchard operated in roles of increasing responsibility including global leadership of research and development, advanced technologies, clinical, quality and regulatory affairs, medical affairs, medical education, health economics and reimbursement. She holds a Ph.D. and an M.S. in Materials Engineering & Materials Science from The University of Texas at Austin, and a B.S. in Ceramic Engineering with a minor in mathematics from Alfred University.
Positions
- Company NameAnika Therapeutics, Inc.Stock CodeANIKPositionExecutive ChairColleagues
- CRCheryl Renee BlanchardExecutive Chair
- SDStephen D. GriffinPresident, Principal Financial Officer, CEO & Director
- IWIan W. McLeodSenior VP, Chief Accounting Officer & Treasurer
- MHMatthew HallExecutive Director of Corporate Development & Investor Relations
- LFLisa FunicielloVP & Chief Human Resources Officer
- SOStephen O. RichardIndependent Director
- JBJohn B. HennemanLead Independent Director
- SLSheryl L. ConleyIndependent Director
- Company NameXilio Therapeutics, Inc.Stock CodeXLOPositionIndependent DirectorColleagues
- RRRene RussoPresident, CEO & Director
- SMSara M. BonsteinIndependent Chairman
- CFChristopher FrankenfieldCFO & COO
- KMKevin M. BrennanSenior Vice President of Finance & Accounting
- UBUli BialuchaChief Scientific Officer
- NMNathan McBrideChief Information Officer
- DJDaniel J. CurranIndependent Director
- JSJames S. ShannonIndependent Director
